Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chinese Academy of Medical Sciences and Peking Union Medical College URAT1 compound 7: sourced facts only. name: "Most compounds potently inhibit the human URAT1 in HEK293 cells, and the most active compound 7 exhibited an IC50 of 0.72 μM, which was much more potent than Lesinurad and comparable to Benzbromarone." [PMID:40669671]; target: "Most compounds potently inhibit the human URAT1 in HEK293 cells, and the most active compound 7 exhibited an IC50 of 0.72 μM, which was much more potent than Lesinurad and comparable to Benzbromarone." [PMID:40669671]; developer: "Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China." [PMID:40669671]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chinese Academy of Medical Sciences and Peking Union Medical College URAT1 compound 7.